Jaguar Health, Inc. (JAGX): Gross Profit
$7.74M
Year ended 2025-12-31
$22.89M
Trailing 12 months to 2026-06-30
-8.0%
3-year compound annual growth
+4.9%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.74M | -20.5% | 2026-04-07, From 2025-01-01 |
| 2024-12-31 | $9.73M | +26.0% | 2026-04-07, From 2024-01-01 |
| 2023-12-31 | $7.72M | -22.3% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $9.94M | +396.4% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $2.00M | -67.2% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $6.11M | +211.6% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $1.96M | +18.7% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $1.65M | -52.6% | 2020-04-03, From 2018-01-01 |
| 2017-12-31 | $3.48M | n/m | 2019-04-10, From 2017-01-01 |
| 2016-12-31 | $89.6K | -33.6% | 2018-04-09, From 2016-01-01 |
| 2015-12-31 | $134.9K | n/a | 2017-02-15, From 2015-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $7.74M | -20.5% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $11.60M | -25.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.47M | +177.7% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.75M | -5.8% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $11.47M | n/a |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $5.07M | -4.8% |
| uniQure N.V. (QURE) | 2025-12-31 | $14.41M | n/a |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $5.74M | -64.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $6.38M | -72.2% |
Compare JAGX, EMMA, TNXP, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗